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Supervisor’s supporting 
comments 
I have always been impressed with Michelle’s ability 
to conduct research in an independent and yet 
highly effective manner. Part of her research in my 
group has examined the use of affinity columns to 
examine drug–protein binding with serum proteins, 
such as human serum albumin. This work is 
extremely important to the fields of pharmaceutical 
chemistry and clinical chemistry in providing the 
data needed for the development of new drugs or 
in the optimization of treatments for patients with new, or existing, drugs. Another topic that Michelle has examined 
in her research is the use of new supports based on monolithic materials and ultrafast-extraction methods for 
affinity-based separations of biological samples and high-throughput screening of drug–protein binding. She was 
the lead author on a review written on this topic and also has several research publications related to this area of 
work. During her graduate studies, Michelle has emerged as a real leader in my group. She has excellent people 
and communication skills and is highly motivated in her pursuit of an advanced degree in analytical chemistry and 
bioana lysis. I have extremely high expectations for her in the future as she continues her career.
Nominated by: David S Hage, University of Nebraska, Department of Chemistry, Hamilton Hall 704, Lincoln, NE 68588, USA
10.4155/BIO.10.175 © 2011 Future Science Ltd
 Q What drove you to choose a career 
in bioana lysis? 
The biological interactions that occur within 
the body have been a topic of interest to me 
since beginning my coursework as a graduate 
student. There are many interactions, such as 
the binding between drugs and proteins, which 
are important in everyday life. Through my 
graduate research experiences in an analytical 
chemistry laboratory, I was further interested in 
the use of analytical techniques to characterize 
these interactions in a quantitative manner. A 
career in bioana lysis allows me to research topics 
that are more biologically related and use ana-
lytical methods to measure the extent of these 
i nteractions in the same environment. 
 Q Describe the main highlights of your 
bioanalytical research, and its importance to 
the bioanalytical community both now and 
in the future.
My research focus is to develop microaf-
finity columns for use in high-performance 
affinity chromatography that can be applied 
towards the creation of new approaches for 
high-throughput ana lysis of drug–protein 
interactions. Microaffinity columns can ana-
lyze these interactions on a much smaller tim-
escale (minutes to seconds). With the use of 
materials such as silica monoliths, I can analyze 
drug–protein interactions on a much smaller 
time scale (milli seconds) by using higher flow 
rates with silica monoliths while immobilizing 
ligands using similar c hemistry schemes as with 
particle-based supports.
My research has also shown that traditional 
longer columns, used in high-performance 
affinity chromatography, can be replaced with 
much shorter columns (from cm to mm) to 
reduce ana lysis times even further. One applica-
tion of shorter columns is the ultrafast-affinity 
extraction for free-drug fraction ana lysis. This 
involves using a short column to rapidly extract 
the free-drug fraction of a drug by taking into 
account the short time required to separate the 
free and protein-bound drug fractions. This is 
also requires the avoidance of any errors due to 
the dissociation of drug–protein complexes as 
they pass through the column. These advance-
ments can play a role in the transition to their 
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 Q Where do you see your career in 
bioana lysis taking you? 
From my experiences with studying biologi-
cally related interactions and using analytical 
techniques, especially high-performance affinity 
chromatography, I have developed a great interest 
in examining other biological systems and using 
this knowledge to aid in the research and develop-
ment of new pharmaceutical agents. I would like 
to continue working in the field of rapid ana lysis 
and high-throughput screening of drug candi-
dates by using different types of support materials 
and taking advantage of the many different avail-
able techniques, such as CE and MS. In addition 
to using other methods, I envision my career in 
bioana lysis incorporating the high-throughput 
settings into a clin ical envir onment, where rapid 
ana lysis times are desired. I see a big part of my 
career to include working with others, whether it 
is through collaborations, training or teaching. 
I will strive to constantly learn something from 
each person I work with and hope to relay a part 
of my knowledge to that person as well.
 Q How do you envisage the field of 
b ioanalysis evolving in the future? 
I see the field of bioana lysis as constantly emerg-
ing with newer, improved techniques and mat-
erials, which, I believe, will help bring about 
more novel ideas and research, especially in areas 
that tie together biology, analytical chemistry 
and biochemistry. I envisage these new develop-
ments will bring more research that can perform 
analyses with fewer amounts of sample require-
ments and faster ana lysis times. With the on-
going research pointing in the direction of more 
analyses performed in a high-throughput setting, 
I hope that the transition into a clinical setting 
will more quickly arise. I also see more research 
conducted through collaborations from several 
different experts in the fields of biology, chemistry 
and biochemistry, in addition to those in medical 
research fields. The research conducted by each 
expert will only aid in more successful progress 
to attain the eventual goal of the research study. 
With more experts from different areas working 
together, I believe that the field of bioana lysis 
will grow quickly and strongly over time as more 
experts contribute to this field and as technology 
continues to improve.
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Bioanalysis Young Investigator Award – 
sponsored by Waters
Each issue of Bioanalysis features a Young Investigator profile, where young 
bioanalysts have the opportunity to describe their work and future aspira-
tions. At the end of each year a winner will be selected by the editorial 
advisory board and will be presented with a $1000 award, sponsored by 
Waters. A travel fund is provided by Waters to assist with the cost of travel 
to the award ceremony.
For a young scientist, being recognized for your hard work at such an early 
stage in your career is a tremendous honor.
Young Investigators should be early career researchers, including Masters 
and Doctorate students, PostDoctorate researchers and those working 
in industry.
If you wish to nominate a Young Investigator, please contact the Editor 
for more details.
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